tiprankstipranks
Advertisement
Advertisement

HK:1477 Stock Latest News

Ocumension Sets August Board Meeting to Approve Interim Results and Consider Dividend
Company AnnouncementsOcumension Sets August Board Meeting to Approve Interim Results and Consider Dividend
2d ago
1477
Ocumension Wins China NMPA Nod for OT-502 Post-Surgery Eye Drug
PremiumCompany Announcements
Ocumension Wins China NMPA Nod for OT-502 Post-Surgery Eye Drug
1M ago
1477
Ocumension CFO Resigns as Company Secretary Role Consolidated Under Chen
PremiumCompany Announcements
Ocumension CFO Resigns as Company Secretary Role Consolidated Under Chen
2M ago
1477
Ocumension Secures Shareholder Backing at AGM and Refreshes Board Leadership
PremiumCompany Announcements
Ocumension Secures Shareholder Backing at AGM and Refreshes Board Leadership
2M ago
1477
Ocumension Details Board and Committee Structure to Highlight Governance
PremiumCompany Announcements
Ocumension Details Board and Committee Structure to Highlight Governance
2M ago
1477
Ocumension Sets 2026 AGM to Approve Results, Board Changes and New Share Mandate
PremiumCompany AnnouncementsOcumension Sets 2026 AGM to Approve Results, Board Changes and New Share Mandate
2M ago
1477
Ocumension Starts Phase III Trial Enrollment for Presbyopia Drug OT-802 in China
Premium
Company Announcements
Ocumension Starts Phase III Trial Enrollment for Presbyopia Drug OT-802 in China
3M ago
1477
Ocumension grants new share options and awards to bolster talent retention
Premium
Company Announcements
Ocumension grants new share options and awards to bolster talent retention
3M ago
1477
Ocumension Enrolls First Patient in China Phase III Trial for FDA-Approved Dry Eye Drug OT-211
PremiumCompany Announcements
Ocumension Enrolls First Patient in China Phase III Trial for FDA-Approved Dry Eye Drug OT-211
5M ago
1477
Ocumension Nearly Doubles Revenue in 2025 and Turns EBITDA Positive on Ophthalmic Portfolio Growth
PremiumCompany Announcements
Ocumension Nearly Doubles Revenue in 2025 and Turns EBITDA Positive on Ophthalmic Portfolio Growth
5M ago
1477
Ocumension Plans Board Refresh With New Independent Director After Wu’s Retirement
PremiumCompany Announcements
Ocumension Plans Board Refresh With New Independent Director After Wu’s Retirement
5M ago
1477
Ocumension Sets March Board Meeting to Approve 2025 Results and Mull Dividend
PremiumCompany Announcements
Ocumension Sets March Board Meeting to Approve 2025 Results and Mull Dividend
5M ago
1477
Ocumension Completes Patient Enrollment for Real-World Study of OT-703 in Hainan
PremiumCompany AnnouncementsOcumension Completes Patient Enrollment for Real-World Study of OT-703 in Hainan
7M ago
1477
Ocumension Increases Treasury Share Holdings to Nearly 21 Million
Premium
Company Announcements
Ocumension Increases Treasury Share Holdings to Nearly 21 Million
8M ago
1477
Ocumension Therapeutics Gains Approval for OT-702 in China
Premium
Company Announcements
Ocumension Therapeutics Gains Approval for OT-702 in China
9M ago
1477
Ocumension Therapeutics Reports Strong Revenue Growth Amid Product Expansion
PremiumCompany Announcements
Ocumension Therapeutics Reports Strong Revenue Growth Amid Product Expansion
12M ago
1477
Ocumension’s OT-301 Achieves Key Milestone in Phase III Trial
PremiumCompany Announcements
Ocumension’s OT-301 Achieves Key Milestone in Phase III Trial
12M ago
1477
Ocumension Therapeutics to Review Interim Results in Upcoming Board Meeting
PremiumCompany Announcements
Ocumension Therapeutics to Review Interim Results in Upcoming Board Meeting
1y ago
1477
Ocumension Therapeutics Updates Nomination Committee
PremiumCompany Announcements
Ocumension Therapeutics Updates Nomination Committee
1y ago
1477
Ocumension Therapeutics Announces Board Composition and Roles
PremiumCompany AnnouncementsOcumension Therapeutics Announces Board Composition and Roles
1y ago
1477
Ocumension Therapeutics Updates Nomination Committee Terms
Premium
Company Announcements
Ocumension Therapeutics Updates Nomination Committee Terms
1y ago
1477
Promising Outlook for Ocumension Therapeutics: Buy Rating Backed by Strategic Developments and Regulatory Milestones
Premium
Ratings
Promising Outlook for Ocumension Therapeutics: Buy Rating Backed by Strategic Developments and Regulatory Milestones
1y ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >